Neurological disorders may be caused for various reasons: genetic defects, birth defects, infections, cancerous tumours, bruising and more. Although the brain and spinal cord are surrounded by strong membranes, wrapped in the bones of the skull and spine and chemically isolated by the Blood Brain Barrier (BBB) are very sensitive if they are damaged.
The injury can also begin with another physical system that has relationships with the nervous system. Cerebral vascular diseases are associated with brain injuries, for example autoimmune deficiencies are related to damage caused to the body by its own immune system.
They can also arise from lifestyle or environmental problems, such as malnutrition or nutritional deficiency in organic living ingredients or other extreme neglect as eating only gobble (junk food). Neurological disorders can be divided according to the main location affected by them, the main area in which there is dysfunction or the cause of the disorder.
Is CBD use only suitable for people with illnesses? Not really! Cannabidiol (CBD) can act in a variety of ways that is beneficial to people who are not defined as blue as well–and is especially beneficial for healthy people seeking to improve their quality of life.
Neurodegenerative diseases of the nervous system are crippling and incurable medical conditions that lead to neurodegeneration and/or death of nerve cells.
This causes problems with movement (called ataxia) or mental dysfunction (called dementias). Recent studies show that activating CB1 and CB2 receptors of the Endo-Cannabinoid System helps protect the body by suppressing the inflammatory process in the brain and reducing high oxidative stress that produces toxic waste around nervous system cells.
CBD is a potent antioxidant and suppresses effective inflammation. Because of these two properties, CBD manages to protect the cells of the central and peripheral nervous systems – (Neuroprotection) Cannabidiol affects the nervous system indirectly, unlike THC it does not bind to the endocannabinoid receptors in the brain and therefore does not have a high sensation.
This feature alone already gives CBD a great advantage among an older population suffering from neurological disorders but the feeling of intoxication associated with smoking cannabis has kept them away from such treatment. Drops, capsules or evaporation of CBD become a common commodity in a variety of forms that are convenient for use even for an older population.
20%
20%
20%
20%
For advice and guidance with Moya-CBD’s team of experts leave us a message
The level of safety of cannabidiol is extremely high: Its known side effects are minor and usually disappear after two or three days from the beginning of treatment. There is no limit whatsoever on the amount of CBD per day, the body cannot reach an CBD “overdose” but it is recommended to avoid a dose higher than 600 mg per day (a rare and almost impossible dose). Unlike other medications that the body often develops intolerance towards, the body does not develop tolerance for CBD and therefore from the moment the correct dose is found that treats the problem and facilitates it, there is no need for an increase in doses.
Companies that currently market products they claim to cure the disease are operating illegally because there is no FDA approved cure for Alzheimer’s or dementia yet. Global scientific research is progressing in understanding the disease and developing therapeutic ways to deal with it. CBD has not yet been tested in a comprehensive clinical study and there is no recommendation for the use of the molecule as a guarantee of cure. The use of CBD by Alzheimer’s patients is common today among many, mainly due to its treatment of a variety of symptoms of the disease, which are often as severe as the disease itself.
Diseases of neurostrucular degasy have one thing in common: Disruption of biochemical processes in nerve cells. Problems with neurotransmitter, oxidative stress, activation of microglia macrogelier cells (ingest cells of the immune system in the brain) and poor functioning of the transmission of vital proteins in the brain and central nervous system cells. It has also been found that in diseases the debasion of nervous system cells there is dysfunction of the Endo-cannabinoid System.
In tests carried out on the brains of people who died as a result of diseases such as Alzheimer’s, Parkinson’s and Huntington, the researchers discovered an imbalance in the Endo-cannabinoid System. Alzheimer’s patients have a shortage of the number of endocannabinoid receptors, especially in areas of neurotransmitteritis and the accumulation of the Amyloid Beta Plaque protein.
This protein is already known in the context of Alzheimer’s disease and recent studies prove that CBD has the ability to lower levels of this protein and its avenous activity. At the same time, it is interesting to note that in undajured areas of the brains of Alzheimer’s patients there is a high concentration of endocannabinoid receptors. That is, there is increased activity of these receptors in areas of the brain where there is no amyloid beta. Similar changes were found in the brains of Parkinson’s patients. The same innovative studies also found that CBD reduced cognitive impairment in the model of Alzheimer’s disease induced in mice in a group that received a regular dose of CBD.
A serious and advanced disease of the central nervous system, especially common (but not only) in the elderly. it manifests itself in slow and persistent adosing until the death of neurons in the brain.
Advanced stage Alzheimer’s disease will inevitably cause the death of the patient, albeit indirectly. in general, Alzheimer’s disease is characterized by cognitive decline. at first, memory impairment is particularly noticeable. over time, other upper functions of the brain are also impaired, such as orientation, thinking ability, and reasoning. as brain decay progresses, the patient’s motor activity is also impaired, as well as the impairment of walking ability, eating ability, and control of the sphincters. in the advanced stages, the patient becomes helpless and needs help with all his actions.
Complications such as infectious diseases or pressure sores eventually lead to the death of the patient with Alzheimer’s disease. great efforts have been made to understand the complex pathophysiological mechanism underlying Alzheimer’s disease but the biochemistry of the disease is not yet fully understood.
As mentioned above, CBD has strong anti-inflammatory activity and antioxidant activity from the strongest in nature, current studies are also conducted on tissue cultures, both in animals and more recently in humans. The findings and conclusions are extremely encouraging.
CBD has been found to prevent the creation of harmful proteins AMYLOID-BETA PLAQUEs in the brains of Alzheimer’s patients, and in reducing protein production and subsidence around nerve cells begins to cure the disease. Around the nerve cells in the brains of Alzheimer’s patients are two proteins that are misproduled. One is amyloid-beta and the other is tau protein.
Cannabidiol works simultaneously in suppressing the production of the amyloid beta protein, corrects a defective processing of tau protein, suppresses chronic inflammatory responses, lowers mitochondrial dysfunction and weakens oxidative stress. CBD can also help treat the various symptoms of the disease such as depression, restlessness, violence, negativeism (refusal to perform any basic action), sleep disorder and more.
There is recent evidence of the role of cannabinoids in the treatment of degenerative disorders, traumatic brain injury and ischemic stroke.
Besides being defined as antioxidants and anti-inflammatories, cannabinoids also exhibit properties that protect nervous system cells. cannabinoids may even promote neurogenesis neurogenesis – the creation of new nerve cells.
The main medical application for the protective effects on the nerve system cells of the cannabis plant, is in degenerative diseases. degenerative diseases occur as a result of a continuous loss of neuronal function.
The second most common disease of neurodegeneration in adults is parkinson’s disease,one of the most common of which is alzheimer’s disease.
Although degenerative disorders are less common in children, they exist, most often as encephalopathy encephalopathy for many degenerative diseases of nervous system cells, inflammation and immune response are one of the main causes that cause damage and dysfunction of neurons. This is also why many degenerative disorders occur at the onset of puberty. currently, there are no treatments for curing degenerative diseases.
At most, medications can mask symptoms and possibly stop the progression of the disease. this is where the protective effects on the nerve cells of cannabis may have a medical role.
In recent years the evidence of antioxidant and anti-inflammatory properties of various cannabinoids has been well established, and our understanding of the role they play as a neurotransmitter regulater, has increased. Therefore, their potential is now being tested as factors that protect nerve cells. So far, cannabinoids have been shown to prevent nerve death with acute nerve damage, including ischemic stroke and traumatic brain injury, as well as providing symptomatic relief from multiple sclerosis, Huntington’s disease and other chronic degenerative diseases.
Antioxidant effects are a proposed mechanism of action by which cannabis may alleviate symptoms associated with neurodegenerative conditions. As early as 1998, researchers demonstrated the antioxidant effects of CBD and noted that it is a stronger antioxidant than ascorbate or tocopherol. Another advantage is that CBD lacks the toxicity associated with tocoprofroll. Link to the study: Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants These findings are relevant because the brain is one of the most vulnerable organs to oxidative stress. Oxidative stress is actually an imbalance in courtship-oxidative situations, causing an excessive amount of free radicals of oxygen. It was hypothesized that oxidative stress is a decisive factor in the onspent of Alzheimer’s.
Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease The same thing was proposed for Parkinson’s disease: Oxidative stress and Parkinson’s disease The anti-inflammatory properties of cannabis may also be considered in the medicinal activity of the plant on the nervous system.
It is thought that activity mediating the CB2 receptor that affects microglia cells in old age reduces neuro-inflammatory mechanisms. See research in link: Cannabinoid Delivery Systems for Pain and Inflammation Treatment. In the current context of treatment for neurodegenerative conditions, anti-inflammatory drugs are sometimes used, especially in the treatment of alzheimer’s. However, so far there have been very mixed results from studies on the efficacy of anti-inflammatories used for this purpose.
A study published in 2002 by Prof. Raphael Meshuulam et al proved that anandamide and 2AG production increased in the brain due to traumatic brain injury. See study link: Cannabinoids and brain injury: therapeutic implications In case of traumatic brain injury (TBI, or intracranial injury), certain substances known to cause nerve damage are produced: tumour necrosis factor-α and free oxygen radicals (ROS).
Anandamide and 2-AG are endogenous cannabinoids produced by the body’s endocannabinoid system. The study showed that anandamide and 2-AG production inhibits the production of potentially harmful substances.
Another study by Prof. Raphael Meshulam examined the inhibitory potential of Anandamide and 2-AG in vivo The study was conducted on mice and rats with traumatic brain injury, with both compounds given to mice and rats damaged in the brain, reducing the extent of brain damage. Decreases in the volume of brain edema (fluid accumulation leading to swelling), infernality (tissue necrosis) and cell death in the atmosphere were observed, along with improved clinical recovery.
The reason why it is relevant to medicinal cannabis is that CBD is now known to increase serum levels of anandamide.
Anandamide is broken down by affluent hydrolysis of fatty acid, Fatty Acid Amide Hydrolase (FAAH), an integral membrane enzyme. Anandamide is transmitted to FAAH enzymes by a protein that binds to FABP (Fatty Acid Binding Protein). FABP are proteins responsible for transferring other molecules through cell membranes. CBD inhibits FABPs, which in turn disrupts the delivery of Anandamide to FAAH, and therefore increases serum levels of anandamide.
Interestingly, researchers have also shown that non-cannabinoid cannabis compounds also inhibit the enzyme Monoacylglycerol Lipase (MAGL), an enzyme responsible for breaking down 2-AG. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
CBD and various other cannabinoids have been repeatedly studied to assess their protective effects on nerve cells during and after an Ischemic Stroke (IS). While there are various studies that indicate that cannabis use can increase the risk of stroke, this phenomenon appears to be limited to a small subs set of sensitive people.
In 27% of these cases, contraction of reversible cerebral blood vessels triggered by the use of cannabinoids may be an important mechanism of stroke. For most, cannabinoid treatments appear to have great potential for alleviating inflammation and oxidative stress due to an IS. CBD is heavily tested as a protective substance on nerve cells for an ischemic stroke.
See sample research: Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke
Recent studies have shown that cannabidiol increases blood flow in the brain following IS and thus helps reduce infarction volume.
Repeated 14-day treatment of CBD (10 mg/kg) has led to the likelihood of hypothermia and protective effects on nerve cells. For this reason, CBD is seen as having greater therapeutic potential than THC in this field of research. It has also been shown that CBD reduces inflammation caused by the release of interlaoquine -1, nitric oxide (nitric oxide) and tumour necrosis factor-α following an ischemic stroke. Just as in the Traumatic Brain Injury, much of the damage caused by IS is due to oxidative stress, caused by the accumulation of ROS due to excessive glutamate signaling.
Both THC and CBD have been shown to be effective antioxidants (as previously proven) that inhibit glutamatergic signaling, thereby reducing the extent of ROS accumulation following an ischemic stroke. However, CBD again shows greater efficacy as an antioxidant and therefore has greater therapeutic potential than THC for neurodegenerative conditions.
Glutamate is the most common neurodevelopmental conductor in the human brain. It is a stimulating neurotransmitter that plays a role in neural pathways involved in the plasticity of synapses. By strengthening or weakening signaling between neurons, glutamate plays an essential role in learning and memory.
Arguably the most important neurotransmitter in the brain, which shapes the way a person retains information and is an important player in long-term potential. However, extremely high glutamate levels cause nerve toxicity (especially mediated by NMDA, AMPA and glutamate receptors) and lead to the formation of secondary damage-causing compounds such as ROS and Tumor necrosis factor-α. It is also known that glutamate activity is reduced in the presence of antioxidants.
Since CBD and THC have been shown to be antioxidants, there is a clear basis for further investigation of cannabinoids in this particular area of neurology. The interactions between different cannabinoids and glutamate signaling system were studied in a study titled Antioxidants That Protect Nerve Cells from Marijuana, published in 2000.
In this study, cannabidiol and several other cannabinoids were studied for potentially protecting nerve cells in rats, in neuronal cultures exposed to toxic levels of glutamate. CBD has introduced the most excellent antioxidant properties to prevent glutamate toxicity
The authors of the study on antioxidants that protect nerve cells from marijuana have also shown that both THC and CBD have increased neural defence and reduced the neurotoxic toxicity of NMDA (N-methyl-D-aspartate receptor) and AMPA receptor (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor). Moreover, the level of neural protection was not increased by the action of antagonists for specific cannabinoid receptors, suggesting that the mechanism of action was independent of the cannabinoid receptors. Previous studies have concluded that CB2 receptors play a role in these important cellular processes. This forms the basis of the idea that selective agonists for this type of receptor (CB2) may act on “both sides of the coin by providing protection for healthy neural cells, or by causing apoptosis of tumour cells. However, CBD does not usually act as an agonist for these receptors, so the potential that protects its nerve cells must be realized elsewhere. CBD has also been shown to reduce hydroperoxide (a type of ROS) toxicity in neuronal cultures, further proving its effectiveness as an antioxidant. Although these tests were performed in vitro, preliminary studies in vivo on brain ischemia in rats indicate that it is effective against all symptoms.
A significant cause of brain injury during the new-born is a hypoxic-ischemic event during childbirth. this occurs when the flow of oxygen and blood to the baby’s brain is interrupted by suffocation, often during childbirth. This devastating condition leads to the deaths of 15-20% of children diagnosed. this condition can also lead to severe neurological impairment such as epilepsy, cerebral palsy, motor function disorder and hyperactivity in another 25%.
The developing brain is much more susceptible to hypoxymical events than the adult brain. because it contains a high concentration of blood vessels and a higher water content, the potential for damage-provoking events like bleeding is greater. Immediately after hypoxic-ischemic brain injury, a set of specific cellular mechanisms that include increased production of glutamate gets underway, leading to cell damage and eventually leads to Excitotoxicity (a type of cell death caused by stimulating glutamate signaling). The exact nature of this process is not yet fully understood because of the complexity of the molecular mechanisms underlying the situation. as such, there are a minority of effective treatment options to mitigate the degree of nerve damage.
However, now, rapid progress in our understanding of the field has led to a new type of protective treatments for nerve cells that will be performed and implemented if proven to be effective. the endocannabinoid system is under review to verify its specific role in providing neural protection to the developing brain.
While the use of cannabinoid treatments in children remains controversial, there have been enough successes in the use of cannabinoids in various situations in children (including epilepsy and cancer) without harmful side effects. As a result, the dispute is now quickly replaced by a consensus among the scientific community that such treatments have feasibility and implementation. Cannabinoids have been offered as good candidates for treating birth brain injuries. In addition to regulating neural reactions, cannabinoids have been shown to regulate vascular dilation due to endothelial cell function and Endothelin activity (endothelin), regulate calcium homeostasis and have significant effects against axytotoxy and anti-inflammatory.
The Protective Properties Of THC Nervous System Cells For The Aging Population
A study published in Nature Medicine in 2017 received a lot of media attention for its slightly unusual claim that THC has new effects on the aging brain. Even Forbes and the Guardian have published articles on this study.
For the purpose of conducting the clinical trial called “Chronic Low Dose of Δ9-Tetrahydrocannabinol (THC) restores cognitive function in older mice,” the researchers introduced low doses of THC into mice of different ages: 2, 12 and 18 months.
In other words, young, mature, old mice. This procedure was performed regularly for four weeks. The size of the dose is significant due to the fact that such small doses do not have psychoactive effects like those resulting from the amounts consumed for recreational use, which are usually larger. During one month, the team led by prof. Andreas Zimer assessed the ability of mice to perform cognitive tasks such as water maze tests.
The team observed the mice’s ability to recall the location of spots or identify other subjects of the same species they had previously been exposed to. Strangely, young mice who did not receive regular low doses of THC performed better in the behaviour tests for memory and learning than younger mice who received regular doses of THC on the other hand, the opposite was for older mice: those who received low and regular doses of THC showed better results in tests than older and older mice who did not receive THC. Cognitive decline as a result of aging is not considered a degenerative disease, although it can be considered pathological. There is almost no treatment for age-related cognitive decline other than maintaining a healthy diet, exercise and brain activity. Rodent studies have shown that THC may in the future have the potential for medical application especially in the treatment of cognitive deficits in the aging population, although studies in humans are required to confirm these results.
This article has primarily investigated THC and CBD Phyto-cannabinoids but there is also research on cannabinoids in their acidic form THCA and CBDA these are predecessors of THC and CBD and exist before the de-carboxilation process occurs. De-carboxylation (heating above 105°C) removes the group of carboxyl acids, making THCA into THC and CBDA into CBD.
See link: An update on PPAR activation by cannabinoids
In this study published in 2017 in the British Journal of Pharmacology, researchers examined the potential of six Phyto- cannabinoids on Tying PPARγ. PPARγ (Peroxisome proliferator-activated receptor) is a nuclear transcription factor and usually has an application for the treatment of diabetes. This is because it regulates insulin response in fat cells.
However, the activation of PPARγ also affects microglia, so it has recently aroused interest in its application in chronic neuro-inflammatory diseases. The study: PPARγ, neuroinflammation, and disease, found that cannabinoid acids bind and activate using PPARγ much better than their de-carboxyne neutral variants. THCA has been found to protect nerves in mice, improving motor deficits and preventing stereotypical degeneration.
The acidic form of THC is not psychoactive, so it is a medical cannabinoid especially relevant to the investigation. Being non-psychoactive, suitable for the broad demographics of people, including children and the elderly, who are most prone to degenerative conditions of nervous system cells.
Like endocannabinoids and Phyto-cannabinoids, attention is now devoted to the potential of various synthetic cannabinoids. For example, a study published in 1999 by the Journal of Neuroscience found that the synthetic cannabinoid atonist R (+) – WIN 55212-2 reduces the loss of neurons in the in vivo lippocampus due to global brain ischemia in rats.
Cannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures The synthetic cannabinoid also reduced the volume of infarction due to focal cerebral ischemia caused by a blockage of the middle brain artery. The less active antiomar (mirror image molecule), S (-) – WIN 55212-3 has been found to be ineffective, And the protective effect of R (+) – WIN 55212-2 can be blocked by the action of the receptor antagonist CB1:”N-(piperidin-1-yl) -5- (4-chlorophenyl) -1- (2, 4-dichlorophenyl) -4-methyl-1H-pyrazole-3-carboxamide-HCl”.
Interestingly, r (+) – win 55212-2 also protected neurons in the cultured cortex from in vitro hypoxia and glucose deficiency, but this effect was not sensitive to the antagonists of the CB1 and CB2 receptors. Much more research is needed to ascertain the exact interactions, but it is clear that there are potential applications for other synthetic cannabinoids as a treatment for brain ischemia, including stroke.
There is much evidence in animal models that indicate the efficacy of a whole range of Phyto- cannabinoids, in the management and reduction of traumatic brain injury, Ischemic Stroke and age-related cognitive decline. Moreover, our understanding of the role played by endogenous cannabinoids anandamide and 2-AG in monitoring inflammation and blood flow processes in the brain. This research channel makes the endocannabinoid system a target for the treatment of neurogenerative conditions.
Although much more research is needed, especially on human subjects, the totality of evidence supporting cannabinoids for the treatment of degenerative disorders continues to grow. the mechanisms of action by which cannabinoids exert protective properties on nerve cells are extensive, complex and worthy of further investigation.
The researchers believe they can leverage the “entourage effect,” which occurs when different cannabinoids are consumed at once, to create an effective treatment for Alzheimer’s. Nearly 6 million Americans now live with Alzheimer’s disease, and by 2050 it is estimated that number could rise to nearly 14 million. Pharmaceutical companies have worked hard to create drugs that can treat the symptoms of this disorder, but without much success. There are currently four FDA-approved drugs to treat AD-related memory loss, but none of these drugs have proven effective.
As the pharmaceutical industry continues to explore traditional drugs, other researchers are looking for natural remedies to solve the problem, Dr. Eitan Russo, a neuroscience researcher and director of research and development at the International Institute for Cannabis and Cannabinoids, has been at the forefront of a new wave of researchers who have examined how cannabis can treat a wide range of diseases, including Alzheimer’s. The cannabis plant contains 167 different chemical compounds called cannabinoids, including THC and CBD, along with a variety of lesser known compounds.
When swallowed, cannabinoids interact with the body’s Endo-Cannabinoid System (ECS), which regulates most physiological systems in the body, including those responsible for immune response, pain and sleep. Researchers have discovered that the endocannabinoid system is dysfunctional in patients with Alzheimer’s and similar disorders.
As CBD, THC also offers a number of unique medical benefits, but access to this cannabinoid remains very limited because this compound is largely responsible for the “High” associated with rashes. Many researchers have balked at studying THC-based therapies due to concerns about the psychoactive effects of this cannabinoid, but Dr. Russo believes that the “entourage effect” created by consuming THC and CBD together can help alleviated these concerns.
In an interview with the CBD Project, Dr. Russo described the entourage effect as a symphony “in which you may think of THC as a soloist with an important part provided by the entire orchestra, but you also have other components that produce harmony that really increases the overall effect and makes cannabis the best possible remedy. When combined CBD with THC it has a numb of the feeling of intoxication (High),” Dr. Russo explained. ‘If someone smokes a substance with both THC and CBD they won’t be as high as they would with THC alone. But, much more importantly, the effect is lasting.
“Because of this effect, an oral preparation containing these two cannabinoids can be taken two or three times a day, as opposed to smoking cannabis consumption, which may need to be used less often due to the feeling of intoxication caused by higher THC concentrations.
Dr. Russo believes now is the time to start clinical trials to examine how these cannabinoids can treat Alzheimer’s. “It has been shown that both THC and CBD interfere with the production of abnormal toxic substances in the brains of such patients, which is quite exciting, because synthetic drugs intended for similar purposes have not yet progressed to medical applications. Both THC and especially CBD are protective factors in known nerve cells that have the potential to slow down or perhaps even stop the neurogenic process.”
As we age, mineral levels accumulate in the brain and body. Although you may think that minerals in the body are a good thing, too many minerals may cause serious health problems down the road. One of the most common minerals in aging bodies is iron, which procludes to accumulate in the brain.
Science tells us that iron buildup can contribute to degenerative diseases such as Parkinson’s disease, Alzheimer’s and dementia. Excessive levels of iron are associated with impairment of cell function, especially mitochondria, which is responsible for producing energy for the cell. It can also disrupt DNA and significantly affect general brain function.
Overloading iron also leads to the production of more free radicals (ROS), which causes inflammation of the brain and even worsens damage to the nervous system. This is why protecting the brain from the harmful effects of iron is seen as a new way to protect the brain from age-related degenerative diseases.
A 2013 study published in the journal Molecular Neurobiology shed some light on how iron affects mitochondria. Mitochondria is stored within the cytoplasm of most cells, and these are responsible for producing much of the chemical energy of the cell.
This is why mitochondria is nicknamed the “cellular power plant” – because its function is to regulate cell processes, which included apoptosis or programmed cell death. In the brains of people suffering from degenerative diseases such as Parkinson’s and Alzheimer’s, it has been observed that there is one thing in common: less chemical energy exists in synapies, where the cells communicate with each other, suggesting that mitochondria may be the key to the fact that the brain’s neuronal circle is well maintained. The presence of too much iron disrupts the dynamics of mitochondria, because it causes it to initiate apoptosis more than normal.
Cannabidiol (CBD) has been shown to help the brain recover from memory impaired causes caused by excessive iron levels. A 2014 study by researchers from the Pontifical Catholic University in Brazil examined the effect of CBD on degenerative diseases. They tested the mitochondria to better understand how CBD can alleviate symptoms in patients suffering from Parkinson’s and Alzheimer’s. The researchers fed rats high amounts of iron, and some were given CBD as a treatment.
Levels of dynamic-like proteins 1 (dynamin) and caspase 3 (caspase) associated with apoptosis were found to be very high due to high iron levels. For this reason, the scientists felt that there was additional evidence to suggest that iron disrupts the balance of mitochondria. The results were promising when they looked at rats treated in the cbd. Protein levels in the yptoccus returned to normal after CBD treatment.
Because these proteins are related to apoptosis, the researchers concluded that CBD is effective at reducing iron effects on brain cells. A much newer study, published in march 2018 in the neuroscience bulletin, supports these findings. Although this study showed that CBD does not disposed of excess iron, it still helped mitochondria manage iron effectively which led to more moderate disruption. In addition, they found that cbd is beneficial in preventing the harmful effects of iron on the DNA of the mitochondria.
The researchers also suggested that CBD’s anti-inflammatory and antioxidant properties help protect its mitochondria and DNA from iron-induced damage, thereby reinforcing the assumption that cbd can be used as a preventive tool for age-related degenerative disorders.
It is clear that iron accumulation in the brain will have a serious impact on your health down the road, especially as we get older, we are much more vulnerable to mental and body disease. Iron is closely linked to the onset of many degenerative diseases, including Alzheimer’s. While there is still a shortage of studies analyzing the effects of CBD on degenerative diseases, the findings we have so far are promising. We certainly need more research done in this area, although there is no harm in the use of CBD to prevent degradation of the brain.
The articles and summaries in this article were translated and processed, led by Dr. Yaakov Waksman , a scientific consultant for Moya Dr. Immunology, a postdoctoral fellow in prof. Raphael Meshulam’s laboratory at the Hebrew university of Jerusalem. The content and studies presented herein are intended to provide information to stakeholders and are not a substitute for professional advice or constitute a certified ghost recommendation.
CBD for Pain: The Natural Analgesic with CBD Oil Chronic pain is one of our most common and, unfortunately, debilitating health issues. It can interfere with a wide range of everyday activities and sap even the strongest will of their
The Role of CBD in Managing Type 2 Diabetes CBD, a non-psychoactive compound found in cannabis, has shown potential benefits for treating type 2 diabetes, a prevalent disease that affects the body’s ability to process blood sugar efficiently. Diabetes Mellitus
CBD for Flight Anxiety: A Natural Alternative It’s understandable to feel anxious during a flight. The turbulence, cramped space, and uncertainty can all contribute to this feeling. But have you considered using CBD as a natural option to help ease
CBG Oil product review Cannabigerol (CBG) is the neutral variant of cannabigerolic acid (CBGA), serving as the “parent compound” in the cannabis plant, from which all other molecules are generated (Mother Cannabinoids molecule). However, it’s found in the plant in
20%
20%
20%
20%
Registered Office: Moya-Consultancy, Guidance & Sales Ltd. Alexandrou Ipsilanti, 15A Larnaca, Cyprus, CY 7103.
Registration No. HE410163.
© Moya-Consultancy, Guidance & Sales Ltd 2021
